Skip to content
Review Open access

Central nervous system efficacy of third generation vs. first generation EGFR-TKIs in the first line treatment for EGFR-mutated non-small cell lung cancer with central nervous system metastases: a systematic review and meta-analysis of phase 3 randomized controlled trials

Sep 2026 · Journal of Thoracic Disease · Vol 18, pp. 1009-1009 · 0 citations · 41 references
Medicine

TL;DR

TGET appeared to be better than FGET for patients with EGFR-mutated NSCLC and CNS metastases, showing improved survival, CNS efficacy, and safety.

Abstract

Background Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases poses significant treatment challenges, as first-generation EGFR-tyrosine kinase inhibitors (TKIs) (FGET) show limited CNS efficacy. Although third-generation EGFR-TKIs (TGET) exhibit superior CNS penetration, the optimal choice for first-line treatment remains debated. This meta-analysis aims to resolve this controversy by directly comparing the CNS efficacy of TGET vs. FGET in patients with EGFR-mutant NSCLC and CNS metastases. Methods A thorough literature search was performed for phase 3 randomized controlled trials (RCTs) comparing TGET and FGET in patients with EGFR-mutated NSCLC and CNS metastases. The primary outcome was CNS-progression-free survival (PFS), and secondary outcomes included overall survival (OS), PFS, CNS response rates, and adverse events (AEs). The study was registered in PROSPERO (ID: CRD42024629581). Results A total of 5 phase 3 RCTs (AENEAS, FLAURA, FURLONG, IBIO-103, and LASER301) met the inclusion criteria. TGET demonstrated superior efficacy in CNS-PFS [hazard ratio (HR): 0.44 (0.33, 0.58), P<0.001], PFS [HR: 0.44 (0.35, 0.54), P<0.001], CNS-objective response rate (ORR) [risk ratio (RR): 1.32 (1.15, 1.52), P<0.001], CNS-complete response (CR) [RR: 3.40 (1.39, 8.28), P=0.007], and CNS-duration of response (DOR) [HR: 0.39 (0.21, 0.73), P=0.003]. The CNS-PFS rate at 4–24 months and PFS at 10–24 months were significantly higher in the TGET group. OS data were available from only 2 of the 5 included phase 3 RCTs. In this analysis, OS numerically favored the TGET group but did not reach statistical significance [HR: 0.79 (0.55, 1.13), P=0.20]. At the cutoff time, more CNS progressions were found in the FGET [RR: 0.59 (0.44, 0.80), P=0.001]. Additionally, less grade 3–5 treatment-related AEs (TRAEs) were found in the TGET group [RR: 0.67 (0.46, 0.98), P=0.04]. Conclusions TGET appeared to be better than FGET for patients with EGFR-mutated NSCLC and CNS metastases, showing improved survival, CNS efficacy, and safety.

Read PDF

Similar papers

Review Open access Sep 2026

A systematic review and network meta-analysis of first-line EGFR-TKI-based combination strategies for EGFR-mutant non-small cell lung cancer with brain metastases

Brain metastases are common in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and remain clinically challenging despite the improved central nervous system activity of third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). Because direct comparisons between active first-line c...

Jia-Yu Ma, Wei-Xin Zhao, Wan-Jing Guo et al. · 0 citations
Review Open access Sep 2026

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non–small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials

No single treatment was clearly superior across all efficacy and safety outcomes, and Osimertinib showed consistent efficacy, while its safety advantage became evident in the sensitivity analysis excluding FLAURA China.

S. Mahato, S. Mudgal, Harminder Singh et al. · 0 citations
Review Open access Oct 2026

Efficacy of immune-oncology combinations versus sunitinib in patients with bone metastases from renal cell carcinoma: A systematic review and meta-analysis of phase III trials with long-term follow-up

Background Bone metastases occur in approximately one-third of patients with metastatic clear-cell renal cell carcinoma (ccRCC) and are associated with poor prognosis. Although immune-oncology (IO)-based combinations are the standard first-line treatment, the relative efficacy of IO plus tyrosine kinase inhibitor (IO+T...

C. F. A. de Albuquerque, Leila Caroline Souza Reis, E. Del Fiol Manna et al. · 0 citations
Open access Aug 2026

Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study

Background Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have become the standard treatment for EGFR-mutant non-small cell lung cancer (NSCLC), but acquired resistance remains inevitable. Current post-progression salvage regimens offer only modest clinical benefits, leaving...

Jia-Jie Sun, Xin-Jing Li, Bing-Xue Wang et al. · 0 citations
Open access Oct 2026

Third-generation EGFR-TKI plus pemetrexed-platinum chemotherapy versus TKI monotherapy as first-line treatment for EGFR-mutant lung adenocarcinoma with brain parenchymal metastases

Objective To evaluate the efficacy and safety of first-line third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) combined with pemetrexed-platinum chemotherapy in patients with EGFR-mutant advanced lung adenocarcinoma and brain parenchymal metastases. Methods A bicenter retrospective cohort study was conducted. A...

Jian-Xi Zhou, Ying-Hao Wang, Kang Wen et al. · 0 citations
Oct 2026

Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights.

BACKGROUND Brain metastases (BM) are frequent in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) and remain challenging after prior EGFR tyrosine kinase inhibitor (TKI) therapy. This exploratory study evaluated high-dose fimmonertinib and explored subtype-specific spatial biology. METHODS iFORCE was a prospec...

M. You, Tong-Ji Xie, Li-Ge Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.